表皮生长因子受体、人类表皮生长因子受体2、人类表皮生长因子受体3表达与非小细胞肺癌预后的关系被引量：12

Correlation between prognosis and expression of EGFR, HER2 and HER3 in non-small cell lung cancer

导出

摘要目的：探讨非小细胞肺癌（NSCLC）患者癌组织中表皮生长因子受体（EGFR）、人类表皮生长因子受体（HER）2、HER3蛋白的表达及其与临床病理因素的关系。方法采用MaxVision免疫组织化学两步法检测156例NSCLC患者癌组织中EGFR、HER2、HER3的表达，研究其与患者临床、病理特征间的关系，并回顾性分析蛋白表达与患者生存的关系。结果 EGFR、HER2、HER3蛋白在NSCLC中均存在过表达，过表达率分别为45.9%（73／156）、30.8%（49／156）和21.4%（37／156）。EGFR过表达多见于鳞状细胞癌、低分化、有淋巴结转移的患者，HER2过表达及三者共同过表达多见于晚期NSCLC患者，三者共同过表达多见于有淋巴结转移的患者。 EGFR、HER2、HER3过表达及三者共同过表达的患者生存率均低于低表达组。结论 EGFR、HER2、HER3过表达及三者共同过表达提示NSCLC患者预后不良。三项联合检测可能比单独检测能更好地预测NSCLC患者预后，指导临床治疗。 Objective To investigate the correlation between the clinical pathological factors and the expression of EGFR, HER2 and HER3 in non-small cell lung cancer tissues. Methods The expression of EGFR, HER2 and HER3 in non-small cell lung cancer tissues was detected by MaxVision immunohistochemical. The relationship between the protein expression and the clinical pathologic characteristics was studied. The correlation between the protein expression and the survival was also retrospectively analyzed. Results Increased expression of EGFR, HER2 and HER3 was detected in the NSCLC tissues and their rates were 45.9 % （73/156）, 30.8 % （49/156） and 21.4 % （37/156）, respectively. There were significant associations between the expression of these proteins and lymph node metastasis, tumor differentiation degree and TNM staging. Conclusions Overexpression of EGFR, HER2, HER3 or all three proteins is a predictor of poor prognosis. Moreover, combined detection of all 3 markers may work better than the individual detection in the prediction of the prognosis to guide the clinical treatment.

作者张坤宁路军赵宏颖金木兰

机构地区首都医科大学附属北京朝阳医院病理科

出处《肿瘤研究与临床》 CAS 2016年第2期73-77,89,共6页 Cancer Research and Clinic

关键词癌非小细胞肺受体表皮生长因子人类表皮生长因子受体2 人类表皮生长因子受体3 预后 Human EPIDERMAL growth factor receptor-2 Human EPIDERMAL growth factor receptor-3 Carcinoma,non-small-cell lung Receptor,epidermal growth factor Prognosis

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献14

1Bublil EM, Yarden Y, The EGF receptor family : spearheading a merger of signaling and therapeutics [ J ]. Curr Opin Cell Biol, 2007, 19 ( 2 ) : 124-134. DOI : 10.1016/j.ceb.2007.02.008.
2Bethune G, Bethune D, Ridgway N, et al. Epidermal growth factor receptor ( EGFR ) in lung cancer: an overview and update [ J ]. J Thorac Dis, 2010, 2 ( 1 ) : 48-51. DOI:10.3978/j.issn.2072- 1439.2010.02.01.017.
3Lee HI, Xu X, Choe G, et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas : Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study [J]. Lung Cancer, 2010, 68(3): 375-382. DOI:10.1016/j. lungean.2009.07.014.
4Minami T, Kijima T, Satoshi K, et al. Overcoming ehemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody- dependent cell-mediated cytotoxicity and antiangiogenesis [ J ]. Sci Rep, 2013 10.1038/srep02669. VEGF-targeted 2669. DOI :.
5Onn A, Correa AM, Gilcrease M, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer [ J ]. Chn Cancer Res, 2004, 10 ( 1 pt 1 ) : 136-143. DOI: 10.1158/1078-0432.CCR-0373-3.
6Cheng CM, Tsuneyama K, Matsui K, et al. Cytoplasmic expression of c-erbB2 in non-small cell lung cancers [ J ]. Virchows Arch, 2005, 446 ( 6 ) : 596-603. DOh 10.1007/s00428-005-1258-7.
7Amin DN, Campbell MR, Moasser MM. The role of HER3,the unpretentious member of the HER family, in cancer biology and cancer therapeutics [ J ]. Semin Cell Dev Biol, 2010, 21 ( 9 ) : 944- 950. DOI : 10.1016/j.semcdb.2010.08.007.
8Koutsopoulos AV, Mavroudis D, Damhaki KI, et al. Simultaneous expression ofc-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome [J]. Lung Cancer, 2007, 57 (2): 193-200. DOI:10.1016/j. lungcan.2007.03.009.
9Rickman OB, Vohra PK, Sanyal B, et al. Analysis of erbB receptors in pulmonary carcinoid tumors [ J ]. Clin Cancer Res, 2009, 15 ( 10 ) : 3315-3324. DOI: 10.1158/1078-0432.CCR-08-2549.
10Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targeting antibodies [ J ]. Exp Cell Res, 2010, 316 (7) : 1083- 1100. DOI: 10.1016/j.yexcr.2010.01.009.